Company Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C).
The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1.
Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Feb 13, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 534 |
| CEO | Mark Goldsmith |
Contact Details
Address: 700 Saginaw Drive Redwood City, California 94063 United States | |
| Phone | 650 481 6801 |
| Website | revmed.com |
Stock Details
| Ticker Symbol | RVMD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001628171 |
| CUSIP Number | 76155X100 |
| ISIN Number | US76155X1000 |
| Employer ID | 47-2029180 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark A. Goldsmith Ph.D. | Chief Executive Officer, President and Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn J.D. | Chief Operating Officer |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research and Development |
| Xiaolin Wang | Executive Vice President of Development |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Walter Reiher Ph.D. | Chief Information Officer |
| Jan Smith Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |